BIND Biosciences, Inc. to Present at American Association for Cancer Research 2012 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, that are capable of up to a ten-fold increase in drug concentration at tumor sites, announced today that a poster presentation on its lead drug candidate BIND-014, has been selected for a late-breaking clinical research presentation at the American Association for Cancer Research (AACR) 2012 Annual Meeting taking place March 31-April 4, 2012 in Chicago, IL. In addition, BIND Biosciences will participate in an NCI/NIH sponsored session on materials characterization for cancer treatment and diagnosis.